Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 8032865, 10 pages
https://doi.org/10.1155/2017/8032865
Research Article

In Vitro Evaluations and In Vivo Toxicity and Efficacy Studies of MFM501 against MRSA

1Antimicrobial Laboratory, Anti-Infective Branch, Bioactivity Programme, Natural Products Division, Forest Research Institute Malaysia (FRIM), 52109 Kepong, Selangor, Malaysia
2Faculty of Applied Sciences, Universiti Teknologi MARA (UiTM), 40450 Shah Alam, Selangor, Malaysia
3Organic Synthesis Laboratory, Institute of Science, Universiti Teknologi MARA (UiTM), 40450 Shah Alam, Selangor, Malaysia
4Biotherapeutic Branch, Bioactivity Programme, Natural Products Division, Forest Research Institute Malaysia (FRIM), 52109 Kepong, Selangor, Malaysia
5Pharmacy Programme, Sultan Azlan Shah Allied Health Sciences College, 31250 Tanjung Rambutan, Perak, Malaysia

Correspondence should be addressed to Saiful Azmi Johari; ym.vog.mirf@imzalufias

Received 9 January 2017; Revised 4 March 2017; Accepted 9 March 2017; Published 27 April 2017

Academic Editor: Paul M. Tulkens

Copyright © 2017 Saiful Azmi Johari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. A. Johari, M. Mohtar, S. A. Syed Mohammad et al., “In vitro inhibitory and cytotoxic activity of MFM 501, a novel codonopsinine derivative, against methicillin-resistant Staphylococcus aureus clinical isolates,” BioMed Research International, vol. 2015, Article ID 823829, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Tetz and V. Tetz, “In vitro antimicrobial activity of a novel compound, Mul-1867, against clinically important bacteria,” Antimicrobial Resistance and Infection Control, vol. 4, article 45, 2015. View at Publisher · View at Google Scholar
  3. G. A. Pankey and L. D. Sabath, “Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections,” Clinical Infectious Diseases, vol. 38, no. 6, pp. 864–870, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. E. B. Chahine and A. O. Nornoo, “Ceftobiprole: the first broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam,” Journal of Experimental and Clinical Medicine, vol. 3, no. 1, pp. 9–16, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Kisgen and D. Whitney, “Ceftobiprole, a broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA),” P and T, vol. 33, no. 11, pp. 631–641, 2008. View at Google Scholar · View at Scopus
  6. D. Kouretas, “Toxicity tests alternative methods in toxicology,” 2013, http://slideplayer.com/slide/6276815/.
  7. B. Tamba, G. Foltea, M. Leon, and R. Iliesu, “Determination of drug toxicity in animals,” 2013, http://webmail.umfiasi.ro/Cercetare/CentreDeCercetare/Documents/Carte%20Experimental%20models%20in%20rodents/15.pdf.
  8. P. A. Botham, “Acute systemic toxicity—prospects for tiered testing strategies,” Toxicology in Vitro, vol. 18, no. 2, pp. 227–230, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Frimodt-Møller, J. D. Knudsen, and F. Espersen, “The mouse peritonitis/sepsis model,” in Handbook of Animal Models of Infection: Experimental Models in Antimicrobial Chemotherapy, O. Zak and M. A. Sande, Eds., pp. 127–136, Academic Press Avon, New York, NY, USA, 1999. View at Google Scholar
  10. M. A. Seleem, A. M. Disouky, H. Mohammad et al., “Second-generation phenylthiazole antibiotics with enhanced pharmacokinetic properties,” Journal of Medicinal Chemistry, vol. 59, no. 10, pp. 4900–4912, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. G. R. Siragusa, “Statistical validation of the track-dilution plating method from ground beef and carcass surface samples,” Journal of Rapid Methods and Automation in Microbiology, vol. 7, no. 3, pp. 155–161, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. B. D. Jett, K. L. Hatter, M. M. Huycke, and M. S. Gilmore, “Simplified agar plate method for quantifying viable bacteria,” BioTechniques, vol. 23, no. 4, pp. 648–650, 1997. View at Google Scholar · View at Scopus
  13. Organization for Economic Co-Operation and Development (OECD), Guideline for the Testing of Chemicals, Revised Draft Test Guideline 420, Acute Oral Toxicity—Fixed Dose Procedure, OECD, Paris, France, 2000.
  14. United Nations, A Guide Globally Harmonized System of Classification and Labelling of Chemicals (GHS), United Nations, New York, NY, USA, 5th edition, 2013.
  15. W. B. Im, S. H. Choi, J.-Y. Park, S. H. Choi, J. Finn, and S.-H. Yoon, “Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent,” European Journal of Medicinal Chemistry, vol. 46, no. 4, pp. 1027–1039, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. A. P. Desbois, C. G. Gemmell, and P. J. Coote, “In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections,” International Journal of Antimicrobial Agents, vol. 35, no. 6, pp. 559–565, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. D. F. Basri, L. W. Xian, N. I. Abdul Shukor, and J. Latip, “Bacteriostatic antimicrobial combination: antagonistic interaction between epsilon-viniferin and vancomycin against methicillin-resistant Staphylococcus aureus,” BioMed Research International, vol. 2014, Article ID 461756, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. S. L. Pendland, M. M. Neuhauser, and J. L. Prause, “In vitro bactericidal activity and post-antibiotic effect of ABT-773 versus co-amoxiclav against anaerobes,” Journal of Antimicrobial Chemotherapy, vol. 49, no. 5, pp. 879–881, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. J.-H. Sim, N. S. Jamaludin, C.-H. Khoo et al., “In vitro antibacterial and time-kill evaluation of phosphanegold(I) dithiocarbamates, R3PAu[S2CN(iPr)CH2CH2OH] for R = Ph, Cy and Et, against a broad range of Gram-positive and Gram-negative bacteria,” Gold Bulletin, vol. 47, no. 4, pp. 225–236, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. M. J. Pucci, S. D. Podos, J. A. Thanassi, M. J. Leggio, B. J. Bradbury, and M. Deshpande, “In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 6, pp. 2860–2871, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. M. K. Yadav, S.-W. Chae, G. J. Im, J.-W. Chung, and J.-J. Song, “Eugenol: a phyto-compound effective against methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical strain biofilms,” PLoS ONE, vol. 10, no. 3, Article ID e0119564, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Zajmi, N. Mohd Hashim, M. I. Noordin et al., “Ultrastructural study on the antibacterial activity of artonin e versus streptomycin against Staphylococcus aureus strains,” PLoS ONE, vol. 10, no. 6, Article ID e0128157, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. D. F. Basri, N. Jaffar, N. M. Zin, and L. Santhana Raj, “Electron microscope study of gall extract from Quercus infectoria in combination with vancomycin against MRSA using post-antibiotic effect determination,” International Journal of Pharmacology, vol. 9, no. 2, pp. 150–156, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Ibrahim, A. M. Chahardehi, and S. F. Sulaiman, “Effects of butanol extract of Urtica dioica on MRSA: structural degeneration study,” Journal of Applied Biological Sciences, vol. 7, no. 3, pp. 31–36, 2013. View at Google Scholar
  25. L. A. Onyango, R. Hugh Dunstan, T. K. Roberts, M. M. Macdonald, and J. Gottfries, “Phenotypic variants of Staphylococci and their underlying population distributions following exposure to stress,” PLoS ONE, vol. 8, no. 10, Article ID e77614, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Jenkins, N. Burton, and R. Cooper, “Manuka honey inhibits cell division in methicillin-resistant Staphylococcus aureus,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 11, pp. 2536–2542, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Raju, G. Rao, S. A. Patil, and C. R. Kelmani, “Increase in cell size and acid tolerance response in a stepwise-adapted methicillin resistant Staphylococcus aureus mutant,” World Journal of Microbiology and Biotechnology, vol. 23, no. 9, pp. 1227–1232, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Eftekhar and T. Dadaei, “Biofilm formation and detection of IcaAB genes in clinical isolates of methicillin resistant Staphylococcus aureus,” Iranian Journal of Basic Medical Sciences, vol. 14, no. 2, pp. 132–136, 2011. View at Google Scholar · View at Scopus
  29. M. A. Ansari, H. M. Khan, A. A. Khan, S. S. Cameotra, and M. A. Alzohairy, “Anti-biofilm efficacy of silver nanoparticles against MRSA and MRSE isolated from wounds in a tertiary care hospital,” Indian Journal of Medical Microbiology, vol. 33, no. 1, pp. 101–109, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. Abcam, “Clindamycin phosphate Safety Data Sheet,” 2016, http://www.abcam.com/ps/Products/143/ab143271/Msds/ab143271_CLP1_EN.pdf.
  31. Sigma-Aldrich, “Clarithromycin Safety Data Sheet,” 2016, http://www.sigmaaldrich.com/MSDS/MSDS/DisplayMSDSPage.do?country=MY&language=en&productNumber=C9742&brand=SIGMA&PageToGoToURL=http%3A%2F%2Fwww.sigmaaldrich.com%2Fcatalog%2Fproduct%2Fsigma%2Fc9742%3Flang%3Den.
  32. S. Ogbonnia, G. Mbaka, E. Anyika, O. Osegbo, and N. Igbokwe, “Evaluation of acute toxicity in mice and subchronic toxicity of hydro-ethanolic extract of Chromolaena odorata (L.) King and Robinson (Fam. Asteraceae) in rats,” Agriculture and Biology Journal of North America, vol. 1, no. 5, pp. 859–865, 2010. View at Publisher · View at Google Scholar
  33. A. Singh, T. K. Bhat, and O. P. Sharma, “Clinical biochemistry of hepatotoxicity,” Journal of Clinical Toxicology, vol. S4, article 1, 2011. View at Publisher · View at Google Scholar
  34. M. K. Mugisha, J. G. Ndukui, A. Namutembi, P. Waako, A.-K. B. Karlson, and P. Vudriko, “Acute and sub-acute toxicity of ethanolic leaf extracts of Rumex abyssinica Jacq. (Polygonaceae) and Mentha spicata L. (Lamiaceae),” Pharmacology & Pharmacy, vol. 5, no. 3, pp. 309–318, 2014. View at Publisher · View at Google Scholar
  35. G. Mahajan, B. Thomas, R. Parab et al., “In vitro and in vivo activities of antibiotic PM181104,” Antimicrobial Agents and Chemotherapy, vol. 57, no. 11, pp. 5315–5319, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Spink, D. Ding, Z. Peng et al., “Structure-activity relationship for the oxadiazole class of antibiotics,” Journal of Medicinal Chemistry, vol. 58, no. 3, pp. 1380–1389, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. P. I. O'Daniel, Z. Peng, H. Pi et al., “Discovery of a new class of non-β-lactam inhibitors of penicillin-binding proteins with gram-positive antibacterial activity,” Journal of the American Chemical Society, vol. 136, no. 9, pp. 3664–3672, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. M. A. Banevicius, N. Kaplan, B. Hafkin, and D. P. Nicolau, “Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model,” Journal of Chemotherapy, vol. 25, no. 1, pp. 26–31, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. P. V. Turner, T. Brabb, C. Pekow, and M. A. Vasbinder, “Administration of substances to laboratory animals: routes of administration and factors to consider,” Journal of the American Association for Laboratory Animal Science, vol. 50, no. 5, pp. 600–613, 2011. View at Google Scholar · View at Scopus
  40. B. Gu, T. Kelesidis, S. Tsiodras, J. Hindler, and R. M. Humphries, “The emerging problem of linezolid-resistant Staphylococcus,” Journal of Antimicrobial Chemotherapy, vol. 68, no. 1, pp. 4–11, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Gonzalez-Ruiz, P. Gargalianos-Kakolyris, A. Timerman et al., “Daptomycin in the clinical setting: 8-year experience with Gram-positive bacterial infections from the EU-CORESM registry,” Advances in Therapy, vol. 32, no. 6, pp. 496–509, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. R. M. Humphries, S. Pollett, and G. Sakoulas, “A current perspective on daptomycin for the clinical microbiologist,” Clinical Microbiology Reviews, vol. 26, no. 4, pp. 759–780, 2013. View at Publisher · View at Google Scholar · View at Scopus